Literature DB >> 8986950

Improved methods for quantification of human immunodeficiency virus type 1 RNA and hepatitis C virus RNA in blood using spin column technology and chemiluminescent assays of PCR products.

H J Lin1, T Tanwandee, F B Hollinger.   

Abstract

The quantification of human immunodeficiency virus type 1 (HIV-1) RNA or hepatitis C virus (HCV) RNA has been facilitated by adapting a spin column procedure for sample preparation and the use of chemiluminescent detection of polymerase chain reaction (PCR) products in microtiter plate format. All materials were commercially available and relatively inexpensive. By making a single dilution prior to amplification, concentrations of 500 copies to 2.5 million HIV-1 1 RNA copies per mL and 1,000 copies to 50 million HCV RNA copies per mL could be determined on 140-microL samples. Between-run imprecision employing the improved procedure for HIV-1 RNA was 23%. Correlation of HIV-1 RNA concentrations obtained using chemiluminescent detection with values obtained by colorimetric assay of PCR products was 0.98. Correlation of HCV RNA concentration determined by the spin column-chemiluminescent assay procedure with those obtained by branched DNA methodology was 0.91. Spin columns could be used with serum or plasma containing acid-citrate-dextrose or heparin anticoagulant, but heparinized samples required treatment with heparinase prior to amplification.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 8986950

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  10 in total

1.  Anticoagulants interfere with PCR used to diagnose invasive aspergillosis.

Authors:  Marta E García; Jose L Blanco; Jesús Caballero; Domingo Gargallo-Viola
Journal:  J Clin Microbiol       Date:  2002-04       Impact factor: 5.948

2.  Recombinant human gamma interferon in human immunodeficiency virus-infected children: safety, CD4(+)-lymphocyte count, viral load, and neutrophil function (AIDS Clinical Trials Group Protocol 211).

Authors:  W T Shearer; M W Kline; S L Abramson; T Fenton; S E Starr; S D Douglas
Journal:  Clin Diagn Lab Immunol       Date:  1999-05

3.  Comparison of quantitative competitive PCR with LightCycler-based PCR for measuring Epstein-Barr virus DNA load in clinical specimens.

Authors:  Servi J C Stevens; Sandra A W M Verkuijlen; Adriaan J C van den Brule; Jaap M Middeldorp
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

4.  Intra-assay performance characteristics of five assays for quantification of human immunodeficiency virus type 1 RNA in plasma.

Authors:  H J Lin; L Pedneault; F B Hollinger
Journal:  J Clin Microbiol       Date:  1998-03       Impact factor: 5.948

5.  Clinical evaluation of an in-house reverse transcription-competitive PCR for quantitation of human immunodeficiency virus type 1 RNA in plasma.

Authors:  M Zazzi; L Romano; M Catucci; G Venturi; A De Milito; P E Valensin
Journal:  J Clin Microbiol       Date:  1999-02       Impact factor: 5.948

6.  Quantitative analysis of Epstein-Barr virus load by using a real-time PCR assay.

Authors:  H Kimura; M Morita; Y Yabuta; K Kuzushima; K Kato; S Kojima; T Matsuyama; T Morishima
Journal:  J Clin Microbiol       Date:  1999-01       Impact factor: 5.948

7.  Adaptive immunity is the primary force driving selection of equine infectious anemia virus envelope SU variants during acute infection.

Authors:  Robert H Mealey; Steven R Leib; Sarah L Pownder; Travis C McGuire
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

8.  Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.

Authors:  Roger Paredes; Irene Cheng; Daniel R Kuritzkes; Ruth E Tuomala
Journal:  AIDS       Date:  2010-01-02       Impact factor: 4.177

9.  Epitope specificity is critical for high and moderate avidity cytotoxic T lymphocytes associated with control of viral load and clinical disease in horses with equine infectious anemia virus.

Authors:  Robert H Mealey; Baoshan Zhang; Steven R Leib; Matt H Littke; Travis C McGuire
Journal:  Virology       Date:  2003-09-01       Impact factor: 3.616

10.  Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure.

Authors:  Roger Paredes; Christina M Lalama; Heather J Ribaudo; Bruce R Schackman; Cecilia Shikuma; Francoise Giguel; William A Meyer; Victoria A Johnson; Susan A Fiscus; Richard T D'Aquila; Roy M Gulick; Daniel R Kuritzkes
Journal:  J Infect Dis       Date:  2010-03       Impact factor: 5.226

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.